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Background. Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been
shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan
supplement on glycemic control, lipid profiles and insulin sensitivity in type 2 diabetic patients. Methodology/Principal
Findings. This was a randomized, double-blind, placebo-controlled, cross-over trial and it was conducted between April and
December 2006 in Shanghai, China. Seventy-three type 2 diabetic patients with mild hypercholesterolemia were enrolled into
the study. Patients were randomized to supplementation with flaxseed-derived lignan capsules (360 mg lignan per day) or
placebo for 12 weeks, separated by an 8-week wash-out period. HbA1c, lipid profiles, insulin resistance index and
inflammatory factors were measured. Sixty-eight completed the study and were included in the analyses. The lignan
supplement significantly improved glycemic control as measured by HbA1c (-0.1060.65 % vs. 0.0960.52 %, P=0.001)
compared to placebo; however, no significant changes were observed in fasting glucose and insulin concentrations, insulin
resistance and blood lipid profiles. Urinary excretion of lignan metabolites (enterodiol and enterolactone) was significantly
higher after the lignan supplement intervention compared to baseline (14.2618.1 vs. 1.262.4 mg/mL, P,0.001). Data also
suggested minimal competition between lignan and isoflavones for bioavailability when measured by the excretion
concentrations. Conclusions/Significance. Daily lignan supplementation resulted in modest, yet statistically significant
improvements in glycemic control in type 2 diabetic patients without apparently affecting fasting glucose, lipid profiles and
insulin sensitivity. Further studies are needed to validate these findings and explore the efficacy of lignans on type 2 diabetes.
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INTRODUCTION
Type 2 diabetes is a serious and economically devastating disease.
Over the past few decades its worldwide prevalence has increased
dramatically, especially in the developing countries such as China
and India [1]. Diabetic patients with poor glycemic control suffer
greatly from micro- and macro-vascular complications, especially
cardiovascular diseases (CVD), the major cause of mortality in this
patient population [2]. Furthermore, high prevalence of dyslipi-
demia in type 2 diabetic patients also contributes to elevated CVD
risk [3].
Recently, phytoestrogens have gained increasing attention
because of accumulating evidence suggesting their protective roles
against numerous chronic diseases, including cancers, CVD,
dyslipidemia and diabetes [4,5]. To date, the most well-studied
phytoestrogens are isoflavones and lignans. Dietary lignans are
broadly available in plant-based foods, particularly concentrated in
flaxseed [4]. Several randomized controlled studies showed
beneficial effects of a flaxseed-supplemented diet (30–50 g/day) on
lipid profiles in both normal- and hypercholesterolemic subjects [6–
10]. Recently, two studies reported that secoisolariciresinol digluco-
side (SDG), the major plant lignan in flaxseed [11], significantly
reduced total cholesterol and LDL cholesterol (LDL-C) concentra-
tions in rabbits [12,13]. However, null findings were observed in
a recent study ofa flaxseed-derived lignan supplement (500 mg/day)
on lipid profiles in 22 healthy women [14]. Evidence of flaxseed or
lignans on glucose metabolism is limited. One pilot study reported
that flaxseed mucilage significantly decreased postprandial blood
glucose in young healthy volunteers [15]. In another clinical trial,
flaxseed supplements werealso found to decreaseglucose and insulin
levelsin25hypercholesterolemicpostmenopausalwomen[16].Data
related to lignan supplements on diabetes has been documented
exclusively from animal studies in which SDG significantly
prevented or delayed the onset of diabetes and improved glycemic
control in rats with type 1 [17] and type 2 diabetes [18].
To our knowledge, no clinical trials thus far have determined
the effect of SDG on glycemic control or lipid profiles in type 2
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already consume high intakes of soy-derived isoflavone and may
respond differently to lignan supplements compared to Westerners
[19]. Therefore, we evaluated the effect of a flaxseed-derived
lignan supplement (containing 360 mg/day SDG, equivalent to
27–60 g of whole flaxseed [20]) on indexes of glycemic control,
insulin resistance and lipid profiles in a randomized, double-blind,
placebo-controlled, cross-over study. The dosage was chosen
based upon the dose range of flaxseed which has been used safely
and effectively in previous reported flaxseed clinical trials on
dyslipidemia [6–10].
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Participants
A total of 581 type 2 diabetic patients were screened for inclusion at
the local community medical service centers in urban districts of
Shanghai. Participants were considered eligible if they met the
following criteria: 1) 50–79 years of age (women were required to be
postmenopausal for at least 1-year); 2) LDL-C level $2.9 mmol/L;
and 3) diagnosis of type 2 diabetes, but not using exogenous insulin
for glycemic control. Exclusion criteria were: 1) current or previous
(preceding 6 months) estrogen-use; 2) regularly taking phytoestro-
gen-containing supplements; 3) antibiotic-use in the preceding
3 months; 4) severe renal, liver, heart, pituitary, thyroid or mental
diseases, alimentary tract ulceration or diseases affecting absorption;
or 5) history of cancer, history of drug or alcohol abuse.
Ethics
The study protocol was approved by the Ethics Committee of
Institute for Nutritional Sciences, Chinese Academy of Sciences.
All participants provided signed informed consents.
Interventions
Thirty-seven subjects began lignan supplements and 36 subjects
started on the placebo for 12 weeks. After an 8-week wash-out
period, the participants received the alternative treatment for
another 12 weeks. While on study, participants were instructed to
maintain their habitual diets, levels of physical activity, and use of
prescribed medications. During the 12 weeks, participants as-
signed to the lignan supplements were instructed to take three
lignan capsules (0.6 g/capsule) each day that provided a daily
amount of 360 mg isolated flaxseed lignan. The raw materials of
lignan were donated by Frutarom Netherlands BV (LinumLife
TM
Extra, Veenendaal, The Netherlands) and were produced by
Jarrow Formulas Inc (Flax Essence
TM , Los Angeles). The three
capsules provided 3.7 kilocalories and were comprised of 20%
SDG, 15.6% fat, 3.2% protein, 2.6% fiber and 30% carbohydrate.
Participants randomly assigned to the placebo group were
instructed to take 3 placebo capsules per day, which were
comprised of rice flour (98%) and provided a total of 5.8
kilocalories. Subjects were asked to return any unused capsules
and adherence was assessed by pill counts, as well as by urinary
concentrations of lignan metabolites (for SDG-specific adherence).
Objectives
The objective of the study was to investigate the effect of a flaxseed-
derived lignan supplement on indexes of glycemic control, insulin
resistance and lipid profiles in type 2 diabetic patients.
Outcomes
All participants were scheduled to visit Huadong Hospital every
3 weeks to obtain new capsules, and their adherence and physical
status were evaluated. Dietary intakes were assessed using 3-day
food records which ascertained intakes during 2-weekdays and 1-
weekend day at four timepoints throughout the study (1 week prior
to and during the last week of each intervention period). All food
records were reviewed for completeness and coded by the trained
dietitians who were blinded to the study arms. Energy and nutrient
intakes were calculated using the SY Nutrition Software (Fudan
University, Shanghai, China) based on the local food composition
database. Physical activity level was evaluated by asking the
average times per week spent on several common activities (e.g.
running, jogging, dancing, bicycling) in the last month and each
activity was assigned a metabolic equivalent value (MET)
according to accepted standards [21]. After fasting overnight,
blood pressure and anthropometric parameters (height, weight,
waist and hip circumference) were measured and blood samples
were collected at the beginning and the end of each two
intervention periods. Fasting venous blood samples were collected
in 7-mL EDTA-treated vacutainers for insulin analysis and 7-mL
serum separator vacutainers for measurements of fasting glucose
and lipid profiles. After centrifugation at 2600 6g for 10 min at
4uC, samples were aliquotted and stored at 280uC until batch
analysis. Fasting morning urine samples (50 mL) were collected at
identical timepoints using plastic jugs containing 50 mg ascorbic
acid. Urine samples were aliquotted and stored at 220uC until
processed.
Serum total cholesterol, HDL cholesterol (HDL-C), LDL-C,
triacylglycerol, and glucose were measured using reagents
purchased from Wako Pure Chemical Industries (Osaka, Japan),
serum lipoprotein(a) [Lp(a)], apolipoprotein A-1 and B (apoA1 and
apoB) were measured using kits from Roche Diagnostics
(Mannheim, Germany). All the above assays were performed on
an automatic analyzer (Hitachi 7080, Japan) within one day.
HbA1c was determined by turbidometric immunoinhibition on
packed red blood cells on the automatic analyzer using kits from
Roche Diagnostics [22]. This assay is approved by the US
National Glycohemoglobin Standardization Program and by the
Food and Drug Administration for clinical use. Plasma insulin was
determined by radioimmunoassay (Linco Research, MO). Insulin
resistance was calculated using the Homeostasis Model Assessment
of Insulin Resistance method (HOMA-IR)=(Insulin (mU/
mL)6glucose (mmol/L))/22.5 [23]. Urinary excretion of lignan
metabolites (enterodiol and enterolactone) and isoflavones (genis-
tein and daidzein) was measured using a modified HPLC method
[24,25]. The intra- and inter-assay CVs ranged from 2.3% to
15.8% for enterodiol, enterolactone, genistein and daidzein at
concentrations of 1.0 and 10 mg/mL.
Lp(a) concentrations were measured in 245 serum samples due
to reagent shortage. The values of urinary excretion of lignan or
isoflavone metabolites were replaced by 0.05 mg/mL (half of the
lowest detectable limit) when not detectable.
Sample Size
As there were no extant studies that had investigated the effect of
flaxseed-derived lignans on HbA1c, the sample size was calculated
based on the previous studies of flaxseed on LDL-C concentra-
tions. Using a one-sided 5% significance level, a sample of 67
patients was needed for this cross-over trial, assuming a 10% drop-
out rate. This gave the study 90% power to detect a 5% difference
(0.2 mmol/L) in LDL-C between treatments (assuming a common
SD of 0.5 mmol/L).
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The random allocation sequence was developed using computer
program by a statistician who was not involved in the study. After
enrollment, each participant was randomly given a unique study
number. Randomization and allocation to the treatment or placebo
group was based on the study number. Participants were
randomized to the intervention or the placebo arms using
stratification factors of gender and tertiled LDL-C concentrations
from screening. In detail, women and men were sortedby theirlevels
of LDL-C, respectively. Then randomization was performed using
a block size of 3 and length of 10 for men and length of 16 for
women, respectively. Placebo capsules were almost identical to the
lignancapsulesinsize,shape,color,andtaste.Eachbottleofcapsules
was marked with the participant’s study number, but no product
identifier. Participants, health professionals, statisticians, and other
research staff involved in the trial were blinded to the assignments.
Statistical Methods
Differencesbetweenvaluesafter12-weekinterventionwereanalyzed
in Stata 9.2 (Stata
TM, Texas) using a mixed model analysis of
covariance with treatment (lignan or placebo) and period (first or
second period) as fixed factors, subjects as random factors, and
baseline measurements as covariates. Further fixed terms corre-
sponding to treatment/period interactions were included to test for
any carry-over effect between periods, and treatment/covariate
interaction was included to test whether the treatment effect of
flaxseed lignan varied according to the baseline values of the
covariate. Given the weight-dependent nature of the study end-
points, weight and weight changes were incorporated into the model
as covariates. However the results were not affected and the data are
therefore not shown. Data that were not normally distributed, as
assessed by the Shapiro-Wilks test, were natural-logarithmically
transformed prior to analysis (see table footnotes for details).
Differences before and after treatments were analyzed using paired
Student’s t-test. Pre-post differences in physical activity level, and
habitual energy and nutrient intake were analyzed using ANOVA.
Differences were considered significant at P,0.05.
RESULTS
Participant Flow, Recruitment and Numbers
Analyzed
A total of 581 type 2 diabetic patients were screened for inclusion in
the study (Figure 1). All participants were enrolled between
December 2005 and April 2006 in urban districts of Shanghai.
The participants wereinitially screened via theirhealtharchiveswith
the help of the local community medical service centers. Then
a screening questionnaire and physical examination were performed
to evaluate eligibility. Finally, 73 subjects agreed to participate. Of
the 73 subjects, 70 completed the study and 68 were available for the
final fullanalysis set (FAS).One subjectreceiving lignan capsuleswas
diagnosed with lung cancer one week after the study began and
decided to withdraw, one subject receiving placebo withdrew one
week after the study began because of poor physical status, and one
subject withdrew in the wash-out period following the diagnosis of
tachycardia. One subject receiving lignan capsules and another
receiving placebo at randomization did not fulfill the FAS because of
aneligibility violation (LDL-C,2.9 mmol/L) and werenot included
in the analyses.
Baseline Characteristics
The baseline characteristics of participants are given in Table 1.
Subjects who agreed to participate were not statistically different
from non-participants with regard to age, weight, BMI and gender
(data not shown). Of the 68 participants, 60 were taking oral
hypoglycemic agents, 46 were taking antihypertensive medications
and 5 were taking hypolipidemic agents. The two groups were
similar in all observed variables after randomization, except for
urinary excretion of isoflavone metabolites and antihypertensive
medication usage (data not shown).
Outcomes and Estimation
No carry-over effect was identified for any of the observed results.
Both the lignan capsules and placebo were well-tolerated, and the
overall adherence was 96% during the lignan treatment phase and
94% during the placebo phase.
Dietary intake and physical activity levels Pre- post dietary
intakes of energy, fat, specific classes of fatty acids, protein,
carbohydrate, total fiber and cholesterol are featured according to
treatment (Table 2). No significant differences were observed
between treatment phases over time. Likewise, no differences were
observed for physical activity and other lifestyle practices.
Effects on glycemic control and insulin sensitivity Data of
the study endpoints are shown in Table 3. Lignan supplementation
significantly reduced HOMA-IR by 3.3% compared to baseline.
HbA1c, fasting glucose and insulin concentrations were also reduced
during the lignan treatment phase,though none of the three pre-post
changes reached statistical significance. Compared with the values
after 12-week placebo treatment, HbA1c was significantly reduced
with lignan supplementation, whereas changes in HOMA-IR,
fasting glucose and insulin concentrations were not significantly
different between the two treatments.
Effects on lipid profiles Changes of serum concentrations of
total cholesterol, LDL-C, HDL-C, triacylglycerol, Lp(a), apoA1 and
apoB did not differ over time or between treatment phases (Table 3).
Other effects As anticipated, the flaxseed lignan supplement
significantly increased the urinary excretion of lignan metabolites
compared to the baseline and thus validated pill count results
during the lignan supplement phase. No difference was seen over
time during the placebo phase. Urinary excretion of isoflavone
metabolites showed no differences over time or between the
treatment phases. Likewise, no differences were observed between
treatments for weight, BMI, systolic BP and diastolic BP (Table 3).
Adverse Events
None of the three participants who withdrew from the study was
considered related to the study treatment. Similar numbers of
adverse events occurred during both treatment phases and they
were predominantly gastrointestinal (percentages of the partici-
pants who reported diarrhea, flatulence and nausea were 23%,
32% and 4%, respectively). Blinded reviews conducted on adverse
events found that these occurrences were not attributable to the
capsules, but rather the participants’ health status.
DISCUSSION
Interpretation and Overall Evidence
To the best of our knowledge, the present study is the first to
investigate the effect of flaxseed-derived lignan on glycemic control,
lipid profiles and inflammatory status in type 2 diabetes. We showed
that 12-week supplementation of a flaxseed-derived lignan complex,
which provided 360 mg/day SDG, statistically significantly reduced
HbA1c concentrations in type 2 diabetic patients as compared with
the placebo. However, no effect was observed on fasting glucose and
insulin concentrations, HOMA-IR and blood lipid profiles.
HbA1c, also known as glycosylated hemoglobin, is an indicator of
long-term glycemic control over the past six-to-eight weeks, and has
Lignan and Type 2 Diabetes
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diabetic patients [26]. In the present study, HbA1c concentrations
were reduced by 0.10% compared to baseline, which is consistent
with a study of dietary supplementation of soy protein (containing
132 mg/d isoflavones) in postmenopausal women with type 2
diabetes (from 6.8360.64 % to 6.7860.61%) [27]. Flaxseed lignan
(SDG) has been shown to be effective in preventing or delaying the
development of diabetes mellitus in animal models, which was
thought to be attributable to its strong antioxidant activity [17,18].
SDG was also shown to suppress the expression of the phospho-
enolpyruvate carboxykinase (PEPCK) gene that codes for the rate-
limiting enzyme responsible for gluconeogenesis in the liver [28].
Therefore, morestudies are needed toclarify theefficiencyoflignans
inthe long-termglycemiccontrol,especiallysinceit isnotcompletely
clear whether the relatively small reduction of HbA1c observed in
this study is, in fact real, or due to chance.
The lignan capsules used in the present study were specifically
selected to avoid potential effects of other nutrients and
constituents in flaxseed, such as fiber and a-linolenic acid, which
are also highly concentrated in flaxseed. Owing that the maximum
Figure 1. Study flow chart of the lignan intervention trial.
doi:10.1371/journal.pone.0001148.g001
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far, we selected 360 mg/day of SDG, corresponding to 27–60 g of
whole flaxseed [20], which was safely used in clinical trials for
dyslipidemia [6–10]. Consistent with the results of Hallund et al.
[14] showing no effect of the flaxseed-derived lignan complex on
lipid concentrations in healthy postmenopausal women, we found
little effect of pure flaxseed lignan on lipid concentrations in the
present study. The cholesterol-lowering effect in previously
reported studies [6–10] may be due to fiber, a-linolenic acid or
other flaxseed constituents, or in combination with SDG, since
whole or defatted flaxseeds were used in these studies. Whole
flaxseed contains 28% dietary fiber [29], which has been shown to
reduce total cholesterol and LDL-C concentrations [30]. Studies
using other phytoestrogens (e.g. isoflavones) also found different
impacts when isoflavones-containing soy protein was compared to
isolated isoflavones. A meta-analysis of 38 clinical trials showed
Table 1. Baseline characteristics of 68 type 2 diabetic patients
(full-analysis-set)
......................................................................
Variable Total (n=68) Group A (n=34) Group B (n=34)
Age (years) 63.267.4 63.467.1 63.067.8
Male gender (n, %) 25 (36.8%) 14 (41.2%) 11 (32.4%)
Height (cm) 159.768.2 160.568.6 158.967.8
Weight (kg) 64.2611.0 64.7611.4 63.8610.6
BMI (kg/m




Hip circumference (cm) 94.567.0 94.567.4 94.566.6





















































Table 2. Dietary intake and physical activity levels of 68 type 2
diabetic patients
......................................................................
Variable Lignan treatment Placebo treatment
Week 0 Week 12 Week 0 Week 12
Energy (kcal/day) 19116329 18586365 18406327 18666321
Fat (% of energy) 32663 1 673 1 663 1 66
SFA (g/d) 10641 0 641 0 631 0 63
MUFA (g/d) 14651 4 661 4 651 4 66
PUFA (g/d) 22692 0 692 1 692 1 69
Protein (% of energy) 17631 8 631 7 631 7 63
Carbohydrate (% of
energy)
51665 2 675 2 665 1 66
Total fiber (g/d) 10641 0 631 0 649 64
Dietary cholesterol
(mg/d)
3946153 4396206 4036195 4106171
Physical activity level
(MET-hours/week)
88.0632.7 92.3637.7 89.4632.4 87.6635.4
Data are mean6Standard Deviation. SFA, saturated fatty acids; MUFA,















































































Table 3. Effects of lignan supplemention vs. placebo on glycemic control and lipid profiles in 68 type 2 diabetic patients (full-
analysis-set)
..................................................................................................................................................
Variable Lignan treatment Placebo treatment
Treatment difference
(P value)
Baseline 12 weeks Absolute change Baseline 12 weeks Absolute change
Weight (kg) 64.0611.0 64.5610.8 0.561.3
* 64.1610.9 64.4611.0 0.361.3 0.354
BMI (kg/m
2)
# 25.063.3 25.263.3 0.260.5
* 25.163.3 25.263.5 0.160.5 0.478
Systolic BP (mmHg) 139.3621.4 138.9619.9 20.4615.1 138.0618.6 138.6618.2 0.7611.6 0.268
Diastolic BP (mmHg) 79.2610.7 77.769.5 21.566.7 79.3610.3 79.069.9 20.366.9 0.751
HbA1c (%)
# 7.1761.42 7.0661.15 20.1060.65 7.0161.10 7.1161.29 0.0960.52 0.001
Glucose (mmol/L)
# 8.1262.60 7.8362.33 20.2961.61 7.9062.31 8.0462.52 0.1461.37 0.829
Insulin (mU/mL)
# 13.3764.54 13.0865.38 20.2963.22 13.2865.02 13.2764.93 20.0162.87 0.169
HOMA-IR
# 4.7461.86 4.4962.06 20.2561.55
* 4.5961.91 4.6561.88 0.0661.20 0.142
Cholesterol (mmol/L)
# 5.9760.92 5.8160.90 20.1760.70 5.8360.85 5.7560.85 20.0860.77 0.367
LDL-C (mmol/L) 4.1960.89 4.0860.79 20.1160.74 4.1060.73 4.0160.76 20.0960.71 0.404
HDL-C (mmol/L)
# 1.3860.34 1.3660.30 20.0260.24 1.3760.32 1.3560.34 20.0260.25 0.243
Triacylglycerol (mmol/L)
# 2.2561.23 2.0561.10 20.2061.12 2.0861.18 2.1161.29 20.0160.89 0.720
ApoA1 (mg/dL) 152.2623.2 149.6623.8 22.5620.0 152.4624.8 148.7623.9 23.7619.7 0.751















# 1.2162.39 14.20618.1 13.0618.2
* 1.3762.50 2.3367.32 0.9767.12 ,0.001
Urine isoflavones (mg/mL)
# 2.7063.94 2.6963.67 20.0164.56 2.7764.15 2.6662.54 20.1164.25 0.962
Data are mean6Standard Deviation. BMI, body mass index; BP, blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; apoA1, apolipoprotein A-1; apoB, apolipoprotein B; Lp(a), lipoprotein(a).
*P,0.05 when compared with baseline data.
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cholesterol and LDL-C concentrations [31]. On the other hand,
another meta-analysis found that soy protein with intact
isoflavones improved lipid profiles, while extracted soy isoflavones
had no effect [32]. A recent study also found neutral effects on
blood lipids of isoflavone supplement (132 mg/day) in type 2
diabetic patients [33]. Therefore, it seems that, analogous to soy
protein, other component(s) in flaxseed might be required to
achieve a therapeutic cholesterol-lowering effect.
The major class of phytoestrogens in Asian diets are isoflavones
from soy-rich foods, while in Western diets it is lignan from various
plant-origin foods [19]. Supporting this notion, we found
comparatively higher urinary excretion of isoflavones than lignans
at baseline, which is consistent with a previous study of women in
Shanghai [34]. Lignans and isoflavones as two major classes of
phytoestrogens are metabolized by intestinal microflora before
absorption [11]. However, it remains unclear whether they
compete against each other in terms of their absorption and
metabolism. In our study, the subjects maintained their habitual
intake of soy or soy-products and the lignan supplement did not
affect urinary excretion of isoflavone metabolites. The urinary
excretion of lignan metabolites (14.20618.1 mg/mL, i.e. about
70.95 mmol/day assuming a 1.5-L urine excretion per day) in our
study (360 mg/day isolated lignan) is comparable to the results of
another intervention trial using an isolated lignan complex
(500 mg/day) for 6 weeks in a Western population
(94611 mmol/day) [14]. Therefore, there was no evidence
suggesting that the bioavailablity of lignans and isoflavones
counteract each other. As the intervention was carried out in
diabetic patients, more studies are needed to investigate these
effects among pre-diabetic and healthy subjects in the future.
One limitation of the present study is that the randomization
was based upon the screening results (LDL-cholesterol) rather than
the baseline measurements. However, since the recruitment for
eligible participants was completed within 6 weeks, it was assumed
that the characteristics of the participants would not vary greatly.
Secondly, two interventions were done in the spring and the
autumn, and the possible influence of seasonal variations may not
be fully adjusted even with the cross-over design. Additionally, the
relatively modest changes of HbA1c in the lignan treatment might
not be clinically sufficient and could be artifact or the effect of
regression towards the mean, even when the baseline values have
been incorporated into the statistical models.
Generalizability
In agreement with previous studies [14,33], we found that a 12-
week supplement of a flaxseed-derived lignan providing 360 mg/
day of SDG did not affect blood lipid profiles, insulin resistance,
fasting glucose and insulin concentrations in type 2 diabetic
patients. However, statistically significant reductions in HbA1c
were observed with the lignan treatment, though the magnitude of
improvement may not be clinically meaningful. Given overall
beneficial effects of whole flaxseed consumption for CVD [29] and
wide distribution of dietary lignans in plant-based foods, especially
flaxseed, there is considerable potential to use these whole foods as
adjuvant therapies in type 2 diabetes without apparent side effects.
Meanwhile, further studies are needed to confirm the current
findings in subjects with different metabolic profiles and/or
different ethnic backgrounds.
SUPPORTING INFORMATION
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0001148.s001 (0.05 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0001148.s002 (1.28 MB
PDF)
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